




Rivastigmine Transdermal Patch

Lisidiming Toupitieji

S -N- -N- -3-[1-()]-



C₁₄H₂₂N₂O₂

250.34

[(2-) ,]

/ /

4.6mg/24

1 4.6mg/24

2 9.5mg/24

- 50kg

-

		4.6mg/24	9.5mg/24	13.3mg/24
17.4mg/24			13.3mg/24	17.4mg/24
				1
	9.5mg/24			
/				/
		17.4mg/24	*	
		9.5mg/24		
2				

		1	2			
(≥10%)		(1%~10%	1%)	(0.1%~1%	0.1%)	(0.01%~0.1%
0.01%)		(<0.01%)				
1	B	U				

*	13.3mg/24		
*	17.4mg/24		
**	24	“ ”	
***	24		“ ”

/

	18 6.2	57 18.8	50 17.0	10 3.3	75 12.6
	18 6.2	31 10.2	16 5.4	10 3.3	49 8.2
	8 2.7	23 7.6	16 5.4	4 1.3	31 5.2
	7 2.4	21 6.9	22 7.5	7 2.3	28 4.7
	2 0.7	15 5.0	12 4.1	3 1.0	17 2.9
	10 3.4	13 4.3	18 6.1		

2.2%

3.7%

-

- /
-

3

4.6mg/24

/

/

QT /

•

/

/

/

/

/

/

88% 65

55% 75

/

P450

/

/

/

/

/

β-_____

β-

/

β-

β-

n=75

549

12mg/

/

/

23%

/

/

/

/

24 48

24

10-20

24

ADAS-Cog -
ADCS-CGIC -
ADCS-ADL -

3 24

4

4	3	24		
ITT-LOCF		9.5mg/24 N=251	® 12mg/ N=256	N=282
ADAS-Cog	n=248	n=253	n=281	
±	27.0±10.3	27.9±9.4	28.6±9.9	
24	-0.6±6.4	-0.6±6.2	1.0±6.8	
±	0.005*1	0.003*1		
p				
ADCS-CGIC	n=248	n=253	n=278	
±	3.9±1.20	3.9±1.25	4.2±1.26	
p	0.010*2	0.009*2		
ADCS-ADL	n=247	n=254	n=281	
±	50.1±16.3	49.3±15.8	49.2±16.0	
24	-0.1±9.1	-0.5±9.5	-2.3±9.4	
±	0.013*1	0.039*1		
p				

* p≤0.05
ITT LOCF
1 ADAS-Cog ADCS-ADL
2 CMH van Elteren ADCS-CGIC <4

24 5
ADAS-Cog 4 ADCS-CGIC ADCS-ADL


	%		
	9.5mg/24	12mg/ [®]	
ITT-LOCF	N=242	N=248	N=276
ADAS-Cog 4 ADCS-CGI ADCS-ADL	17.4	19.0	10.5
p	0.037*	0.004*	

* p<0.05

9.5mg/24 12mg/

9.5mg/24


48



	(13.3mg/24h) N = 265	(9.5mg/24h) N = 271	(13.3mg/24h) (9.5mg/24h)
DLSM 95% CI P			

	(13.3mg/24h) N = 265	(9.5mg/24h) N = 271	-	(13.3mg/24h) (9.5mg/24h)
--	-------------------------	------------------------	---	-----------------------------

-48



		NAP-226-90	
	65kg	35kg	2
100kg			

15

15

264670

0535-6717618

0535-6717718

www.luye.cn

_____?

¶

¶

¶

1

¶

¶

¶

¶

¶

¶

24

¶

14

¶

¶

¶

2

¶

3

¶

¶

1

1

?

A


¶


¶

¶

¶

A





6

¶

¶

¶

¶
